R&D Trends

Northwell Health, GE Ventures partner on bioelectronic medicine

Thursday, February 23, 2017

Northwell Health‘s Feinstein Institute for Medical Research has announced a strategic alliance with GE Ventures to support the Feinstein’s Center for Bioelectronic Medicine (CBEM). With this investment, the Feinstein Institute will continue its work in discovering, developing and commercializing new diagnostic and therapeutic solutions in bioelectronic medicine for a wide range of acute and chronic diseases and injuries, including neurodegenerative diseases, cancer, diabetes and hypertension.      

[Read More]

Pediatric hematology-oncology initiative launched in Africa

Tuesday, February 21, 2017

His Excellency the President Lieutenant General Dr. Seretse Khama Ian Khama of the Republic of Botswana, the Honorable Minister Dorcas Makgato of the Ministry of Health and Wellness, the Bristol-Myers Squibb Foundation, Texas Children’s Cancer and Hematology Centers (TXCH) and Baylor College of Medicine International Pediatric AIDS Initiative at Texas Children’s Hospital (BIPAI) through public-private partnerships with the governments of Botswana, Uganda and Malawi, announced a $100 million initiative to create an innovative pediatric hematology-oncology treatment network in southern and east Africa. The comprehensive initiative called Global HOPE (Hematology-Oncology Pediatric Excellence) will build long-term capacity to treat and dramatically improve the prognosis of thousands of children with cancer and blood disorders in southern and eastern Africa.

[Read More]

ACOA awards Appili Therapeutics $2.8M for clinical trials

Tuesday, February 21, 2017

Appili Therapeutics, an anti-infective drug development company, announced that it will be receiving $2,803,148 from the Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund (AIF). This funding will enable Appili to take its first drug, ATI-1501—a taste-masked, oral antibiotic that treats anaerobic infections like Clostridium difficile—through clinical trials to be ready for market approval.

[Read More]

Luxcel Biosciences, Axiogenesis, BMG LABTECH to develop cell metabolism analysis platform

Thursday, February 16, 2017

Three European technology SMEs, together with two research institutions, Oxford University and Imperial College London, have been awarded €2.5 million funding from the European commission under the H2020 Fast Track to Innovation (FTI) pilot, to develop and launch a cell metabolism analysis platform that is predicted to be part of routine in vitro cell biology and drug development. 

[Read More]

Boehringer Ingelheim, Weill Cornell Medicine partner on next generation COPD treatments

Wednesday, February 15, 2017

Boehringer Ingelheim has announced a collaboration with Weill Cornell Medicine to identify new treatment approaches for chronic obstructive pulmonary disease (COPD) in order to develop novel treatments that could possibly halt or even reverse the progression of the disease process. The new, three-year collaboration combines Weill Cornell Medicine’s Department of Genetic Medicine’s unique understanding of chronic airway diseases and experience in the investigation of novel therapeutic concepts for airway repair with Boehringer Ingelheim’s expertise in the discovery and development of new therapies for respiratory diseases. This collaboration is the second collaboration between Boehringer Ingelheim and Weill Cornell Medicine, following prior work in inflammatory bowel disease (IBD).

[Read More]

RCSI, Almac partner on target therapy-resistant cancer tumors

Wednesday, February 15, 2017

RCSI (Royal College of Surgeons in Ireland) and Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, have announced a major research collaboration that aims to gain a new understanding of how to target tumor cells that are resistant to cancer therapies and cause cancer to spread to other parts of the body. The project will explore the potential of a drug, based on initial research by RCSI’s Professor Tracy Robson and developed by Almac Discovery, which is currently undergoing a phase I dose escalation trial for patients with solid tumors. It is expected that the trial will be expanded in a biomarker selected patient population within ovarian cancer, however the drug, ALM201, has the potential to treat a range of other cancers.

[Read More]

Incyte, Agenus amend collaboration agreement

Wednesday, February 15, 2017

Incyte and Agenus have amended the License, Development and Commercialization Agreement that was originally entered into January 9, 2015. The amended agreement converts the ongoing GITR and OX40 antibody programs from co-funded development and profit-sharing arrangements to royalty-bearing programs, with Incyte now responsible for funding and conducting global development and commercialization. Should candidates from either of these two programs be approved, Agenus would now become eligible to receive 15% royalties on global net sales of each approved product.

[Read More]